25 results for “Safety Pharmacology”. Showing 25 of 39,449.
Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine.
safety pharmacology study in cynomolgus monkeys or in vitro in human
The integration of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: A case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs.
Safety pharmacology screening against a wide range of unintended vital
Pharmacological characterization and preclinical evaluation of 11h: a novel, brain-penetrant PDE4 inhibitor for neurological disorders
safety pharmacology encompassing CYP450 inhibition, cardiac ion channel profiling, mutagenicity
Network medicine modeling of the m⁶A regulatory landscape identifies a KLF6-WTAP axis as a therapeutic target in pulmonary fibrosis.
pharmacology and safety remains unclear. METHODS: Guided by a computational
Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis.
safety of pharmacological treatments for psychotic depression. METHODS: In this
Unraveling Network Pharmacology-Based Therapeutics of Anthranilate Sulfonamides via Sirtuins/FOXO3a Cascade in Alzheimer's Disease.
safety profiles. Network pharmacology also revealed the involvement of SA1-4 and key targets
Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer.
pharmacology, efficacy, and safety of capivasertib for the treatment of adults
Phase 1, First-In-Human, Single-/Multiple-Ascending Dose Study of Iluzanebart in Healthy Volunteers.
safety, tolerability, pharmacokinetics, and pharmacological activity in the CNS, supporting
Brain repair mechanisms after cell therapy for stroke.
safety switches and universal (immune evasive) cell transplants, as well as the therapeutic potential of these pharmacologic
TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro.
safety profiles, and cost-effectiveness evaluation. Further pharmacological analysis revealed
[Adverse reactions analysis of Aconiti Lateralis Radix Praeparata and mechanism prediction of cardiac toxicity by network pharmacology].
safety use of aconite through the retrieval of literature about adverse reactions,predict its mechanism of cardiac toxicity by using network pharmacology
Electroacupuncture ameliorates tau-driven cognitive decline by modulating NF-κB/NLRP3 inflammasome signaling in P301S mice.
pharmacological NLRP3 inhibitors hold therapeutic potential for AD, critical barriers-including poor blood-brain barrier penetration, suboptimal target selectivity, and safety
Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132.
pharmacologic profiles of SKB264, including efficacy, pharmacokinetics-pharmacodynamics (PK-PD), safety
New Approaches to the Treatment of Frontotemporal Dementia.
pharmacological approaches to management include lifestyle modifications, speech-, occupational-, and physical therapy, peer and caregiver support, and safety
Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.
BACKGROUND: Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has
Neuroinflammation is responsible for pain in endometriosis - targeting the JAK-STAT pathway and mast cell activation.
pharmacological strategies offer a promising avenue for improving clinical outcomes. Further research is necessary to validate the efficacy and safety
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
pharmacological remission. Patients who had received placebo during REGAIN experienced rapid and sustained improvements during open-label eculizumab (P < 0.0001). These findings provide evidence for the long-term safety
The anti-cancer mechanism of Celastrol by targeting JAK2/STAT3 signaling pathway in gastric and ovarian cancer.
pharmacological mechanism of Celastrol's anticancer effects, with a focus on STAT3 signaling pathway in cancers with high incidence of metastasis. METHODS: The safety
A review of the putative antiseizure and antiepileptogenic mechanisms of action for soticlestat.
safety and efficacy of soticlestat in Dravet syndrome (SKYLINE) and Lennox-Gastaut syndrome (SKYWAY) have recently been completed. The exact mechanism of action by which soticlestat exerts pharmacological
Neurolymphatic clearance in neurodegenerative disease: Emerging mechanisms and potential translational strategies.
pharmacological and microsurgical modulatory techniques remain experimental approaches for neurodegenerative diseases, with a significant potential to improve patients' quality of life. However, further research is warranted to establish their safety
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
safety and efficacy of TDF and emtricitabine for this new indication. A thorough understanding of variability in drug response will help determine future investigations in the field and/or implementation into
NRF2 as a Therapeutic Target in Dermatological Disorders: Mechanisms and Molecules.
pharmacological activation of NRF2 represents a promising therapeutic strategy to counteract oxidative stress-driven skin damage and inflammation; however, continued translational and clinical research is required to optimize formulations, dosing
Therapeutic indications for HDAC6 inhibitors in the peripheral and central nervous disorders.
pharmacological inhibition of HDAC6 is a promising approach for treating both PNS and CNS disorders, given its involvement in neurodegeneration and aging-related cellular processes. Despite the progress
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
pharmacologic activities of DS-8201a were evaluated and compared with T-DM1 in several HER2-positive cell lines and patient-derived xenograft (PDX) models. The mechanism of action
Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer's Disease and Down Syndrome.
pharmacological inhibitors of DYRK1A might be able to correct memory/learning disorders in people with AD and DS. Starting from a marine sponge natural product, Leucettamine B, Perha Pharmaceuticals has optimized